Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: all of below~* adults aged 18-70 years~* serum anti-HCV antibody (+)~* HCV RNA detectable by PCR~* compensated liver disease (Child-Pugh class A)~Exclusion Criteria: any of below~* HCV genotype other than 1, 2, or 3~* acute hepatitis C~* decompensated cirrhosis or hepatocellular carcinoma~* other liver disease such as hepatitis A or B, or autoimmune hepatitis~* HIV Ab(+)~* severe depression or other psychiatric disease~* previous organ transplantation~* absolute neutrophil count (ANC) \< 1,000 cells/mm3 or platelet count \< 75,000 cells/mm3, or hemoglobin (Hb) \< 13 g/dL for men, \<12 g/dL for women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Korean CHC (Type: EXPERIMENTAL): Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.

Based on this trial design, predict the completion outcome and termination type (if applicable).